Medizinische Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, 04103 Leipzig, Germany.
Dtsch Arztebl Int. 2010 Aug;108(34-35):578-82. doi: 10.3238/arztebl.2011.0578. Epub 2010 Aug 29.
Treatment with pancreatic enzymes must be based on an understanding of the normal physiology and pathophysiology of exocrine pancreatic function, as well as of the diseases that cause exocrine pancreatic insufficiency of either a structural or a functional type. These include chronic pancreatitis, pancreatic cancer, cystic fibrosis, pancreaticocibal asynchrony after gastric or pancreatic surgery, and celiac disease.
Selective review of the literature.
Exocrine pancreatic insufficiency can cause meteorism, diarrhea, steatorrhea, and weight loss. All of these manifestations are non-specific except steatorrhea. Enzyme supplementation is indicated only for the treatment of demonstrated pancreatic dysfunction; unfortunately, however, no sensitive and specific pancreatic function tests are currently available. As a result, pancreatic enzyme supplementation is considered to be indicated on pragmatic grounds when, for example, the patient is suffering from diarrhea and weight loss and has been demonstrated to have a disease leading to exocrine pancreatic insufficiency. To be acceptable for clinical use, a pancreatin preparation must satisfy the following criteria: it must be enterically coated, so that it will not be destroyed by gastric acid; mix well with gastric chyme; exit the stomach simultaneously with chyme; and be rapidly released from its enteric coating upon entering the duodenum. Although there have been no large-scale, randomized comparative studies of different types of pancreatin preparation, the current clinical preference is for enterically coated micropellets or minitablets with a diameter of 2 mm or less. The initial dosage is 20 000 to 40 000 units of lipase taken once or twice per meal, with dose adjustment afterward as needed. The dose can be raised, and a proton-pump inhibitor can be added on.
There is still no simple test that can be used to diagnose pancreatic exocrine insufficiency with certainty. The treatment is symptomatic; its goals are to lessen steatorrhea and reverse weight loss.
胰腺酶的治疗必须基于对胰腺外分泌功能的正常生理学和病理生理学的理解,以及引起结构或功能性外分泌胰腺不足的疾病的理解。这些疾病包括慢性胰腺炎、胰腺癌、囊性纤维化、胃或胰腺手术后的胰腺-十二指肠协同失调以及乳糜泻。
文献选择性回顾。
外分泌胰腺不足可引起腹胀、腹泻、脂肪泻和体重减轻。除脂肪泻外,所有这些表现均无特异性。仅当证实存在胰腺功能障碍时才建议使用酶补充治疗;然而,目前尚无敏感和特异性的胰腺功能检查方法。因此,当患者出现腹泻和体重减轻且被证实患有导致外分泌胰腺不足的疾病时,出于实用主义的考虑,认为需要补充胰腺酶。为了便于临床应用,胰酶制剂必须满足以下标准:它必须是肠溶包衣的,以免被胃酸破坏;与胃食糜充分混合;与食糜同时离开胃;并在进入十二指肠时迅速从肠衣中释放出来。尽管尚未对不同类型的胰酶制剂进行大规模、随机对照研究,但目前的临床偏好是使用肠溶微丸或直径为 2 毫米或以下的迷你片剂。初始剂量为每餐 20000 至 40000 单位的脂肪酶,一次或两次,随后根据需要进行剂量调整。可以提高剂量,并可以添加质子泵抑制剂。
仍然没有简单的测试可以用于确定诊断胰腺外分泌不足。治疗是对症治疗;其目标是减轻脂肪泻和逆转体重减轻。